ObjectiveTo explore the methodologies employed in studies assessing transition of care interventions, with the aim of defining goals for the improvement of future studies.DesignSystematic review of comparative studies assessing transition to adult care interventions for young people with chronic conditions.Data sourcesMEDLINE, EMBASE, ClinicalTrial.gov.Eligibility criteria for selecting studies2 reviewers screened comparative studies with experimental and quasi-experimental designs, published or registered before July 2015. Eligible studies evaluate transition interventions at least in part after transfer to adult care of young people with chronic conditions with at least one outcome assessed quantitatively.Results39 studies were reviewed, 26/39 (67%) published their final results and 13/39 (33%) were in progress. In 9 studies (9/39, 23%) comparisons were made between preintervention and postintervention in a single group. Randomised control groups were used in 9/39 (23%) studies. 2 (2/39, 5%) reported blinding strategies. Use of validated questionnaires was reported in 28% (11/39) of studies. In terms of reporting in published studies 15/26 (58%) did not report age at transfer, and 6/26 (23%) did not report the time of collection of each outcome.ConclusionsFew evaluative studies exist and their level of methodological quality is variable. The complexity of interventions, multiplicity of outcomes, difficulty of blinding and the small groups of patients have consequences on concluding on the effectiveness of interventions. The evaluation of the transition interventions requires an appropriate and common methodology which will provide access to a better level of evidence. We identified areas for improvement in terms of randomisation, recruitment and external validity, blinding, measurement validity, standardised assessment and reporting. Improvements will increase our capacity to determine effective interventions for transition care.
Discussion and conclusion This study highlights international consensus on prescription practice in pediatrics. The use of this tool in everyday practice could reduce the risk of inappropriate prescription. The impact of the diffusion of POPI tool will be assessed in a prospective multicentric study. 9 (2-9) 94.4 9 (3-9) 92.9 Rectal administration of paracetamol as a first-line treatment 8 (1-9) 78.9 8.5 (1-9) 85.7 The combined use of two NSAIDs 9 (1-9) 94.4 9 (7-9) 100 Opiates to treat migraine attacks 9 (3-9) 89.5 9 (8-9) 100 Omission of prescription Failure to give sugar solution to newborn babies and infants under four months old two minutes prior to venipuncture 9 (2-9) 88.9 9 (8-9) 100 Failure to give an osmotic laxative to patients being treated with morphine for a period of more than 48 hours 8 (2-9) 82.4 9 (8-9) 100 Urinary infections Inappropriate prescription Antibiotic prophylaxis following an initial infection without complications (except in the case of uropathy) 9 (1-9) 94.7 9 (9-9) 100 Antibiotic prophylaxis in the case of asymptomatic bacterial infection (except in the case of uropathy) 9 (1-9) 94.7 9 (8-9) 100 Vitamin supplements and antibiotic prophylaxis Inappropriate prescription Fluoride supplements prior to six months of age 9 (1-9) 94.7 9 (9-9) 92.9 Mosquitos Inappropriate prescription Citronella (lemon grass) essential oil 9 (1-9) 82.4 8.5 (1-9) 85.7 Anti-insect bracelets to protect against mosquitos and ticks 9 (1-9) 83.3 9 (1-9) 85.7 Ultrasonic pest control devices, vitamin B1, homeopathy, electric bug zappers, sticky tapes without insecticide 9 (1-9) 88.2 9 (1-9) 85.7 Omission of prescription Mosquito nets and clothes treated with pyrethroids 9 (1-9) 83.3 9 (1-9) 85.7 Digestive nausea, vomiting or gastroesophageal reflux problems Inappropriate prescription Metoclopramide 9 (3-9) 94.4 9 (3-9) 92.9 Domperidone 8 (2-9) 77.8 8.5 (3-9) 85.7 Oral administration of an intravenous proton pump inhibitor (notably by nasogastric tube) 9 (1-9) 94.7 9 (8-9) 100 Gastric antisecretory drugs to treat gastroesophageal reflux, dyspepsia, the crying of newborn babies (in the absence of any other signs or symptoms), as well as faintness in infants 9 (1-9) 94.7 9 (6-9) 92.9 9 (5-9) 94.4 9 (7-9) 100 Antibiotic treatment for a sore throat, without a positive rapid diagnostic test result, in children less than three years old 9 (1-9) 88.9 9 (5-9) 92.9 Antibiotics for-nasopharyngitis-congestive otitis-sore throat before three years of age-laryngitis-as a first-line treatment for acute otitis media showing few symptoms, before two years of age 9 (3-9) 82.4 9 (5-9) 92.9 Antibiotics to treat otitis media with effusion (OME), except in the case of hearing loss or if OME lasts for more than three months 9 (1-9) 84.2 9 (7-9) 100 Corticosteroids to treat acute suppurative otitis media, nasopharyngitis, or strep throat 9 (1-9) 94.7 9 (8-9) 92.9 Nasal or oral decongestant (oxymetazoline, pseudoephedrine, naphazoline, ephedrine, tuaminoheptane, phenylephrine) 9 (4-9) 82.4 9 (5-9) 92.9 H1-antagonists with sedative or atr...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.